The effect of mirabegron, a potent and selective β3- adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 39, Issue 1, 2014, Pages 43-52

  Krauwinkel, Walter ^a   Dickinson, James ^a   Schaddelee, Marloes ^a   Meijer, John ^a   Tretter, Reiner ^a   Van De Wetering, Jeroen ^b   Strabach, Gregory ^c   Van Gelderen, Marcel ^a  

^a Astellas Pharma Global Development   (Netherlands)

^b PRA Health Sciences   (Netherlands)

^c SGS Aster   (France)

Author keywords

CYP2D6; Desipramine; Metoprolol; Mirabegron; Overactive bladder

Indexed keywords

2 HYDROXYDESIPRAMINE; ALPHA HYDROXYMETOPROLOL; CYTOCHROME P450 2D6; DESIPRAMINE; METOPROLOL; MIRABEGRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ACETANILIDES; ADOLESCENT; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DESIPRAMINE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDDLE AGED; THIAZOLES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 84897053329     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-013-0133-1     Document Type: Article

References (36)

1. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw D, Wieling J, Hekster YA, Burger DM (2005) Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78:664-674 (Pubitemid 41773642)
2. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291 (Pubitemid 27312427)
3. Eltink C, Lee J, Schaddelee MP, Zhang W, Meijer J, van Marle S, Grunenberg N (2012) Single dose pharmacokinetics and absolute bioavailability of mirabegron, a selective and potent b3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 50:838-850
4. European Medicines Agency (2010) Draft Guideline on the Investigation of Drug Interactions. http://www.emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/05/WC500090112.pdf. Accessed 28 January 2013
5. Evert B, Griese EU, EichelbaumM(1994) Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 4:271-274
6. Gueorguieva I, Jackson K, Wrighton SA, Sinha VP, Chien JY (2010) Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. Br J Clin Pharmacol 70:523-536
7. Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466-477 (Pubitemid 30327485)
8. Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D (2007) Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 63:159-163 (Pubitemid 46147057)
9. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532 (Pubitemid 20278099)
10. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM (2000) Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67:283-291 (Pubitemid 30176387)
11. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355 (Pubitemid 26288625)
12. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C (2013) Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a Randomised European-Australian Phase 3 Trial. Eur Urol 63:283-295. doi:10.1016/j.eururo. 2012.10.016
13. Laine K, De Bruyn S, Björklund H, Rouru J, Hänninen J, Scheinin H, Anttila M (2004) Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol 59:893-898 (Pubitemid 38333680)
14. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J. Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the in Vivo Metabolism of Mirabegron, a β3-adrenoceptor agonist. Clin Drug Invest. 2013 (Accepted)
15. Lennard MS, Tucker GT, Silas JH, Woods HF (1986) Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 16:435-447 (Pubitemid 16076722)
16. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmacol 20:555-566 (Pubitemid 16184094)
17. Nichols AI, Fatato P, Shenouda M, Paul J, Isler JA, Pedersen RD, Jiang Q, Ahmed S, Patroneva A (2009) The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 49:219-228
18. Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2012) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. doi:10.1016/j.juro.2012.10.017 (Epub ahead of print)
19. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90-98 (Pubitemid 24120706)
20. Sallee FR, Pollock BG (1990) Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 18:346-364 (Pubitemid 20134542)
21. Sawamoto T, Lee J, Alak A et al (2011) Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 89(Suppl 1):S21
22. Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624 (Pubitemid 16124372)
23. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243-246 (Pubitemid 23171910)
24. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1995) The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 117:413-416
25. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1996) Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 18:60-64 (Pubitemid 26033359)
26. Steijns LS, Van Der Weide J (1998) Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44:914-917 (Pubitemid 28213128)
27. Steiner E, Spina E (1987) Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 42:278-282 (Pubitemid 17155732)
28. Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE (2011) Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol 51:389-396
29. Takasu T,UkaiM,Sato S,Matsui T,Nagase I,Maruyama T,Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2- hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647. doi:10.1124/jpet.106.115840 (Pubitemid 46624504)
30. Takusagawa S, Scheinkoenig J, Buckley D, Miyashita A, Iwatsubo T, Usui T (2012a) In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica 42:1187-1196
31. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T (2012b) Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 40:815-824
32. Takusagawa S, Yajima K, Miyashita A, Iwatsubo T, Usui T (2012c) Identification of human CYP isoforms and esterases involved in the metabolism of mirabegron (YM178), a novel selective β3-adrenoceptor agonist. Xenobiotica 42(10):957-967
33. US Food and Drug Administration (2012) Draft guidance for industry on drug interaction studies-study design, data analysis, implications for dosing and labeling recommendations. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 28 January 2013
34. van Gelderen E, Li Q, Meijer J, Schaddelee MP, Takusagawa S, Sugawara T, de Koning P (2009) An exploratory comparison of the single dose pharmacokinetics of the β3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 85(Suppl 1):S88
35. Wieling J, Tamminga WJ, Sakiman EP,Oosterhuis B,Wemer J, Jonkman JH (2000) Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. Ther Drug Monit 22:486-496 (Pubitemid 30622124)
36. Yuen KH, Wong JW, Yap SP, Billa N (2001) Estimated coefficient of variation values for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther 39:37-40 (Pubitemid 32048061)